Compare · IKNX vs TMO
IKNX vs TMO
Side-by-side comparison of Ikonics Corporation (IKNX) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- IKNX operates in Miscellaneous, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $232.26B, about 2879.9x IKNX ($80.6M).
- TMO has hit the wire 10 times in the past 4 weeks while IKNX has been quiet.
- TMO has more recent analyst coverage (25 ratings vs 0 for IKNX).
- Company
- Ikonics Corporation
- Thermo Fisher Scientific Inc
- Price
- $33.98-0.96%
- $628.06-0.13%
- Market cap
- $80.6M
- $232.26B
- 1M return
- -
- +12.31%
- 1Y return
- -
- +28.54%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- n/a
- News (4w)
- 0
- 10
- Recent ratings
- 0
- 25
Ikonics Corporation
IKONICS Corporation develops, manufactures, and sells photosensitive liquids and films for screen printing, awards and recognition, and dye sublimation markets worldwide. It operates through four segments: Chromaline, IKONICS Imaging, Digital Texturing, and Advanced Material Solutions. The company sells screen printing films, emulsions, and inkjet receptive films, photo resistant films, art supplies, glass, and related abrasive etching equipment to end users and distributors. It also provides sound deadening and weight reduction technology to the aerospace and electronics industries; products and services for etched composites, ceramics, glass, and silicon wafers; and digital texturing technology for putting patterns and textures into steel molds for the plastic injection molding and prototyping. IKONICS Corporation markets and sells its products directly, as well as through domestic and international distributors, magazine advertising, trade shows, and the internet. The company was formerly known as The Chromaline Corporation and changed its name to IKONICS Corporation in December 2002. IKONICS Corporation was founded in 1952 and is based in Duluth, Minnesota.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest IKNX
- Ikonics Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Ikonics Corporation filed SEC Form 8-K: Financial Statements and Exhibits (Amendment)
- SEC Form 4: Prager Paul B. was granted 30,879,973 shares
- SEC Form 4: New Jason Griffin was granted 1,429,257 shares
- SEC Form 4: Langlais Kerri M. was granted 864,701 shares
- SEC Form 4: Khan Nazar M. was granted 7,609,366 shares
- SEC Form 4: Carter Walter E. was granted 21,752 shares
- SEC Form 3: New insider Stammtisch Investments Llc claimed ownership of 30,879,973 shares
- SEC Form 3 filed by new insider Prager Paul B.
- SEC Form 3 filed by new insider Prager Lisa A.
Latest TMO
- Sr. Vice President & CFO Meyer James covered exercise/tax liability with 31 shares, decreasing direct ownership by 0.53% to 5,830 units (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 20,000 shares at a strike of $309.63 and sold $12,561,823 worth of shares (20,000 units at $628.09) as part of a pre-agreed trading plan, decreasing direct ownership by 0.00% to 123,925 units (SEC Form 4)
- Sr. VP and Chief HR Officer Britt Lisa P. sold $7,014,093 worth of shares (11,440 units at $613.12) and exercised 11,440 shares at a strike of $418.32, decreasing direct ownership by 0.00% to 14,784 units (SEC Form 4)
- Executive Vice President Shafer Michael D exercised 25,500 shares at a strike of $370.58 and sold $15,300,000 worth of shares (25,500 units at $600.00) as part of a pre-agreed trading plan (SEC Form 4)
- Thermo Fisher Scientific Completes Sale of its Microbiology Business to Astorg
- VP & Chief Accounting Officer Holmes Joseph R. exercised 420 shares at a strike of $309.63 and sold $245,620 worth of shares (420 units at $584.81) (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 275 shares at a strike of $309.63 and sold $2,862,002 worth of shares (4,883 units at $586.12) as part of a pre-agreed trading plan (SEC Form 4)
- Sr. VP and Chief HR Officer Britt Lisa P. exercised 5,850 shares at a strike of $309.63 and sold $3,393,000 worth of shares (5,850 units at $580.00), decreasing direct ownership by 0.00% to 14,784 units (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 10,000 shares at a strike of $309.63 and sold $8,616,967 worth of shares (15,000 units at $574.46) as part of a pre-agreed trading plan, decreasing direct ownership by 0.00% to 123,925 units (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 10,000 shares at a strike of $309.63 and sold $8,628,434 worth of shares (15,000 units at $575.23) as part of a pre-agreed trading plan, decreasing direct ownership by 0.00% to 123,925 units (SEC Form 4)